SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

AIRCOIN is trending amidst massive community enthusiasm for its newly launched AirLock initiative, a unique community-owned supply control mechanism. Participants are actively locking up a significant portion of the supply, signaling strong long-term conviction and aiming to redefine the memecoin space on Solana with transparent, HODL-focused fundamentals.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta ($KTA) is trending as the community keenly discusses its potential to become a foundational layer for global financial plumbing. Its impressive transaction speeds, compliance-first architecture, and recent live integration with Stripe's Bridge for seamless fiat on/off-ramps are driving conversation. Many see $KTA as an undervalued, asymmetric opportunity poised to facilitate institutional flows and real-world asset interoperability across various ecosystems.

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

SATOSHI CRYPTO is currently a top trending asset as the community fervently embraces its identity as the tokenization of Satoshi Nakamoto, the pivotal figure in crypto. Supporters are buzzing about its deeply undervalued status, viewing it as the "Bitcoin of memes" and the very "culture of the entire industry" across ETH, Base, and SOL. This passionate sentiment projects it as a monumental, timeless narrative set for substantial recognition.

World Mobile Token (WMTX) is the utility token that powers the World Mobile network, a decentralized mobile network at the forefront of the DePIN space. World Mobile aims to connect the world by leveraging blockchain technology and a sharing economy. By becoming an AirNode operator or a token staker, anyone can earn rewards for providing telco services to customers or securing the network. The World Mobile network is disrupting the trillion-dollar telco industry and creating a more inclusive, sustainable, and privacy-respecting wireless service for everyone.

World Mobile Token

World Mobile Token ($WMTX) is trending due to recent listings on major exchanges like Coinbase and Kraken, significantly boosting its market accessibility. The community is also buzzing about its Unity program, which enables users to operate nodes and earn rewards, reinforcing its real-world utility in decentralized global connectivity.

Advanced Energy Industries, Inc. engages in the provision of power electronics conversion products. Its products include AC-DC power supply units, DC-DC conversion, high voltage amplifiers and power supplies, plasma power, controllers, sense, and measurement. The company was founded by Douglas S. Schatz in 1981 and is headquartered in Denver, CO.

Advanced Energy Industries Inc.

Advanced Energy Industries is trending strongly after delivering a robust earnings report, primarily driven by exceptional growth in its data center computing business, which benefits directly from the accelerating AI sector. Analysts have swiftly upgraded the stock and raised price targets, fueling community discussions about its continued upside potential while also acknowledging technical indicators showing overbought conditions. The company's critical role in powering advanced semiconductor and industrial applications solidifies its position as a key beneficiary in the burgeoning AI infrastructure market.

Theoriq is a decentralized Web3 project that focuses on creating an ecosystem of autonomous AI agents that can collaborate in multi-agent swarms to perform complex tasks. Unlike traditional AI, these agents work together, validate each other’s outputs, and operate on-chain, making them especially useful for applications in DeFi, on-chain analytics, and automation.  The project combines AI intelligence with blockchain technology, enabling developers, users, and data providers to contribute, earn rewards, and participate in decentralized governance. Its goal is to democratize AI by creating a community-driven, secure, and scalable network where autonomous agents can execute tasks and generate value efficiently.

Theoriq

Theoriq (THQ CRYPTO) is trending following its recent Coinbase listing, which has sparked intense debate among the community regarding its extreme volatility and price action. Many traders are actively discussing the significant post-listing drops, while others remain optimistic, citing low circulation and potential for future upward movement despite initial losses.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano is actively trending amid a vigorous community debate contrasting its established research-driven ecosystem with emerging high-performance, compliance-first infrastructure solutions designed for institutional finance. Many discussions highlight newer platforms' superior transaction speed and seamless fiat integration, leading to divided community sentiment ranging from deep frustration over ADA's current performance to bullish perspectives advocating for accumulation during perceived dips.

Investment Managers Series Trust II - Tradr 2X Short TSLA Daily ETF

Tradr 2X Short TSLA Daily ETF

TSLQ is trending as the community intensely scrutinizes TSLA's valuation and long-term prospects, with many anticipating a significant market correction for the underlying asset. Traders are actively leveraging this 2x inverse ETF to capitalize on bearish sentiment, driven by speculation around TSLA's operational clarity, future earnings, and the impact of expiring EV tax credits.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is actively discussed following its Revuforj drug being named "Best New Drug" at the Scrip Awards 2025 and recent FDA approvals for additional acute leukemia indications. The community is highly anticipating further positive data from upcoming ASH conference presentations, fueling strong buyout speculation, particularly with Incyte, and highlighting its perceived undervaluation compared to oncology peers and high short interest.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

AVNT is trending following its recent Robinhood listing and its prominent role as a perpetual decentralized exchange built on Coinbase's Base chain. The community is heavily split, with many highlighting its undervalued status compared to competitors like Aster and Hyper, citing strong use cases and staking. Conversely, a vocal group labels it a "pump and dump" or "scam" due to past price performance and concerns over coin unlocks, fueling intense debate about its immediate future.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$WGRX EXECUTIVE SUMMARY
Investment Thesis:
Wellgistics Health (WGRX) is a platform distributor for affordable pharmaceuticals,
with Brenzavvy (bexagliflozin) serving as proof-of-concept. The company&#39;s business
model is characterized by 50% gross margins (buy at wholesale, sell at retail) and
targets a 20% operating margin after SG&amp;A, with no R&amp;D burden. While Brenzavvy
alone generates modest returns ($126M Year 3 revenue, $19.9M net income, $0.221
EPS), the true value multiplier comes from replicating the platform across multiple drug
categories. By Year 3, a multi-drug portfolio (Brenzavvy, GLP-1 complements, obesity
drugs, generics, and other brands) could generate $301M in revenue, $47.6M in net
income, and $0.528 EPS—representing a $5.53/share premium and a $9.51/share fair
value at 18× P/E (vs. $3.98 for Brenzavvy-only).
Key value drivers:
• 50% gross margins on pharmaceutical distribution (wholesale to retail spread).
• 20% operating margin achievable across all drug categories (no R&amp;D, fixed
platform cost).
• 6,500+ pharmacies already in network; minimal incremental cost per new drug.
• EinsteinRx AI scales seamlessly to identify patients and prescribers for new drug
categories.
• Network effects: Each drug added deepens physician engagement and
accelerates adoption of subsequent drugs.
• First-mover advantage in AI-driven prescription routing for affordable drugs.
I. BRENZAVVY-ONLY MODEL: 50% GROSS, 20%
OPERATING MARGIN (90M SHARES)
Revenue Ramp (Year 1–3)
Based on company guidance of $3–4M/month by Month 5, with growth to 3× that run
rate ($12M/month) by Year 3:
Year 1 Detailed Monthly Build-Out
Month Revenue Month Revenue
1 $0.2M 7 $5.0M
2 $0.5M 8 $5.2M
3 $1.0M 9 $5.4M
4 $2.0M 10 $5.6M
5 $4.0M 11 $5.8M
6 $4.5M 12 $6.0M
Year 1 annual revenue: $42M (exit run rate: $6.0M/month)
3-Year P&amp;L: Brenzavvy Only
Metric Year 1 Year 2 Year 3
Revenue $42M $102M $126M
Gross profit (50% margin) $21.0M $51.0M $63.0M
Metric Year 1 Year 2 Year 3
Operating expenses (30% of revenue) $12.6M $30.6M $37.8M
Operating income (20% margin) $8.4M $20.4M $25.2M
Taxes (21%) $1.76M $4.28M $5.29M
Net income $6.64M $16.12M $19.91M
EPS (90M shares) $0.074 $0.179 $0.221
Brenzavvy-only valuation (Year 3):
• At 15× P/E: $3.32/share
• At 18× P/E: $3.98/share
• At 20× P/E: $4.42/share
Key insight: Even Brenzavvy alone, with your 50/20 margin structure and no R&amp;D,
generates solid returns: $0.22 EPS by Year 3, implying a $3.98 fair value per share at
18× P/E.
II. MULTI-DRUG PLATFORM: THE REAL VALUE DRIVER
Critical thesis: Brenzavvy is proof-of-concept for WGRX&#39;s platform. Once validated, the
same 6,500-pharmacy network and EinsteinRx AI can be leveraged to distribute
multiple drug categories with zero incremental R&amp;D and minimal fixed cost additions.
Multi-Drug Revenue Build-Out
WGRX&#39;s platform expansion targets:
1. Brenzavvy (SGLT2 inhibitor)
• Addressable: 1M cash-pay + 3M high-copay patients = 4M total
• Year 3 revenue: $126M
2. GLP-1 Complement Products (via Tollo Health partnership)
• Addressable: 12M patients on GLP-1s; addressing side effects (nausea,
fatigue, GI distress)
• Year 2 launch: $15M → Year 3: $80M
3. Low-Cost Generics &amp; Alternatives
• SGLT2 generics (canagliflozin, empagliflozin generics entering market)
• GLP-1 generics (launching 2027–2028)
• Year 2: $5M → Year 3: $30M
4. Obesity/Weight Loss Drugs
• Compounded versions, supplement stacks, lower-cost alternatives to
tirzepatide/semaglutide
• Year 3 launch: $25M
5. Other Affordable Brand Partnerships
• EinsteinRx identifies additional manufacturers and patient segments
• Year 2: $5M → Year 3: $40M
Platform Revenue Progression
Drug Category Year 1 Year 2 Year 3 Growth
Brenzavvy $42M $102M $126M 3.0×
GLP-1 Complements — $15M $80M Launch → scale
Low-cost Generics — $5M $30M Launch → scale
Obesity/Weight Loss — — $25M New category
Drug Category Year 1 Year 2 Year 3 Growth
Other partnerships — $5M $40M Incremental
TOTAL PLATFORM $42M $127M $301M 7.2×
III. MULTI-DRUG PLATFORM EARNINGS (90M
SHARES)
Key Assumptions
• Blended gross margin: 50% (Brenzavvy), declining to 48–49% (due to lower-
margin generics and complements)
• Operating margin target: 20% of total platform revenue (uniform across all
categories)
• Rationale: Each new drug leverages the same 6,500 pharmacies and EinsteinRx
AI; minimal incremental SG&amp;A
• No R&amp;D costs: No drug development; platform is purely distribution and AI-
driven routing
3-Year P&amp;L: Multi-Drug Platform
Metric Year 1 Year 2 Year 3
Total revenue $42M $127M $301M
Blended gross margin 50.0% 48.0% 49.0%
Metric Year 1 Year 2 Year 3
Gross profit $21.0M $61.0M $147.5M
Operating expenses (30% of revenue) $12.6M $38.1M $90.3M
Operating income (20% margin) $8.4M $25.4M $60.2M
Taxes (21%) $1.76M $5.33M $12.64M
Net income $6.64M $20.07M $47.56M
EPS (90M shares) $0.074 $0.223 $0.528
Multi-drug platform valuation (Year 3):
• At 15× P/E: $7.93/share
• At 18× P/E: $9.51/share
• At 20× P/E: $10.57/share
IV. PLATFORM ECONOMICS: WHY THIS WORKS
1. Zero Marginal Distribution Cost
Brenzavvy economics (Year 1):
• Fixed cost to on-board 6,500 pharmacies, train staff, set up systems: ~$5M
• Per-patient delivery cost: negligible (pharmacy already integrated)
GLP-1 complements, generics, obesity drugs (Year 2–3):
• No incremental pharmacy on-boarding (already in network)
• Add new drug to existing systems: minimal cost
• Gross margins: 48–50% (same distribution economics)
• Operating margin: 20% (same SG&amp;A leverage)
Result: Each $100M of new platform revenue adds approximately:
• Gross profit: $49–50M
• Operating income: $20M (at 20% margin)
• Net income: $15.8M (after 21% taxes)
• EPS contribution: $0.176 per share (on 90M shares)

StockTwits for iOS

Wellgistics Health Inc.

 EXECUTIVE SUMMARY
Investment Thesis:
Wellgistics Health (WGRX) is a platform distributor for affordable pharmaceuticals,
with Brenzavvy (bexagliflozin) serving as proof-of-concept. The company's business
model is characterized by 50% gross margins (buy at wholesale, sell at retail) and
targets a 20% operating margin after SG&A, with no R&D burden. While Brenzavvy
alone generates modest returns ($126M Year 3 revenue, $19.9M net income, $0.221
EPS), the true value multiplier comes from replicating the platform across multiple drug
categories. By Year 3, a multi-drug portfolio (Brenzavvy, GLP-1 complements, obesity
drugs, generics, and other brands) could generate $301M in revenue, $47.6M in net
income, and $0.528 EPS—representing a $5.53/share premium and a $9.51/share fair
value at 18× P/E (vs. $3.98 for Brenzavvy-only).
Key value drivers:
• 50% gross margins on pharmaceutical distribution (wholesale to retail spread).
• 20% operating margin achievable across all drug categories (no R&D, fixed
platform cost).
• 6,500+ pharmacies already in network; minimal incremental cost per new drug.
• EinsteinRx AI scales seamlessly to identify patients and prescribers for new drug
categories.
• Network effects: Each drug added deepens physician engagement and
accelerates adoption of subsequent drugs.
• First-mover advantage in AI-driven prescription routing for affordable drugs.
I. BRENZAVVY-ONLY MODEL: 50% GROSS, 20%
OPERATING MARGIN (90M SHARES)
Revenue Ramp (Year 1–3)
Based on company guidance of $3–4M/month by Month 5, with growth to 3× that run
rate ($12M/month) by Year 3:
Year 1 Detailed Monthly Build-Out
Month Revenue Month Revenue
1 $0.2M 7 $5.0M
2 $0.5M 8 $5.2M
3 $1.0M 9 $5.4M
4 $2.0M 10 $5.6M
5 $4.0M 11 $5.8M
6 $4.5M 12 $6.0M
Year 1 annual revenue: $42M (exit run rate: $6.0M/month)
3-Year P&L: Brenzavvy Only
Metric Year 1 Year 2 Year 3
Revenue $42M $102M $126M
Gross profit (50% margin) $21.0M $51.0M $63.0M
Metric Year 1 Year 2 Year 3
Operating expenses (30% of revenue) $12.6M $30.6M $37.8M
Operating income (20% margin) $8.4M $20.4M $25.2M
Taxes (21%) $1.76M $4.28M $5.29M
Net income $6.64M $16.12M $19.91M
EPS (90M shares) $0.074 $0.179 $0.221
Brenzavvy-only valuation (Year 3):
• At 15× P/E: $3.32/share
• At 18× P/E: $3.98/share
• At 20× P/E: $4.42/share
Key insight: Even Brenzavvy alone, with your 50/20 margin structure and no R&D,
generates solid returns: $0.22 EPS by Year 3, implying a $3.98 fair value per share at
18× P/E.
II. MULTI-DRUG PLATFORM: THE REAL VALUE DRIVER
Critical thesis: Brenzavvy is proof-of-concept for WGRX's platform. Once validated, the
same 6,500-pharmacy network and EinsteinRx AI can be leveraged to distribute
multiple drug categories with zero incremental R&D and minimal fixed cost additions.
Multi-Drug Revenue Build-Out
WGRX's platform expansion targets:
1. Brenzavvy (SGLT2 inhibitor)
• Addressable: 1M cash-pay + 3M high-copay patients = 4M total
• Year 3 revenue: $126M
2. GLP-1 Complement Products (via Tollo Health partnership)
• Addressable: 12M patients on GLP-1s; addressing side effects (nausea,
fatigue, GI distress)
• Year 2 launch: $15M → Year 3: $80M
3. Low-Cost Generics & Alternatives
• SGLT2 generics (canagliflozin, empagliflozin generics entering market)
• GLP-1 generics (launching 2027–2028)
• Year 2: $5M → Year 3: $30M
4. Obesity/Weight Loss Drugs
• Compounded versions, supplement stacks, lower-cost alternatives to
tirzepatide/semaglutide
• Year 3 launch: $25M
5. Other Affordable Brand Partnerships
• EinsteinRx identifies additional manufacturers and patient segments
• Year 2: $5M → Year 3: $40M
Platform Revenue Progression
Drug Category Year 1 Year 2 Year 3 Growth
Brenzavvy $42M $102M $126M 3.0×
GLP-1 Complements — $15M $80M Launch → scale
Low-cost Generics — $5M $30M Launch → scale
Obesity/Weight Loss — — $25M New category
Drug Category Year 1 Year 2 Year 3 Growth
Other partnerships — $5M $40M Incremental
TOTAL PLATFORM $42M $127M $301M 7.2×
III. MULTI-DRUG PLATFORM EARNINGS (90M
SHARES)
Key Assumptions
• Blended gross margin: 50% (Brenzavvy), declining to 48–49% (due to lower-
margin generics and complements)
• Operating margin target: 20% of total platform revenue (uniform across all
categories)
• Rationale: Each new drug leverages the same 6,500 pharmacies and EinsteinRx
AI; minimal incremental SG&A
• No R&D costs: No drug development; platform is purely distribution and AI-
driven routing
3-Year P&L: Multi-Drug Platform
Metric Year 1 Year 2 Year 3
Total revenue $42M $127M $301M
Blended gross margin 50.0% 48.0% 49.0%
Metric Year 1 Year 2 Year 3
Gross profit $21.0M $61.0M $147.5M
Operating expenses (30% of revenue) $12.6M $38.1M $90.3M
Operating income (20% margin) $8.4M $25.4M $60.2M
Taxes (21%) $1.76M $5.33M $12.64M
Net income $6.64M $20.07M $47.56M
EPS (90M shares) $0.074 $0.223 $0.528
Multi-drug platform valuation (Year 3):
• At 15× P/E: $7.93/share
• At 18× P/E: $9.51/share
• At 20× P/E: $10.57/share
IV. PLATFORM ECONOMICS: WHY THIS WORKS
1. Zero Marginal Distribution Cost
Brenzavvy economics (Year 1):
• Fixed cost to on-board 6,500 pharmacies, train staff, set up systems: ~$5M
• Per-patient delivery cost: negligible (pharmacy already integrated)
GLP-1 complements, generics, obesity drugs (Year 2–3):
• No incremental pharmacy on-boarding (already in network)
• Add new drug to existing systems: minimal cost
• Gross margins: 48–50% (same distribution economics)
• Operating margin: 20% (same SG&A leverage)
Result: Each $100M of new platform revenue adds approximately:
• Gross profit: $49–50M
• Operating income: $20M (at 20% margin)
• Net income: $15.8M (after 21% taxes)
• EPS contribution: $0.176 per share (on 90M shares)